These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 9532331)

  • 1. [Meropenem (from foreign publications)].
    Kuznetsovoĭ SM
    Antibiot Khimioter; 1998; 43(1):43-5. PubMed ID: 9532331
    [No Abstract]   [Full Text] [Related]  

  • 2. [Meropenem].
    Shatunov SM; Belousov IuB
    Antibiot Khimioter; 1996 Jun; 41(6):49-61. PubMed ID: 9054330
    [No Abstract]   [Full Text] [Related]  

  • 3. Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics.
    Bradley JS
    Pediatr Infect Dis J; 1997 Mar; 16(3):263-8. PubMed ID: 9076812
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
    Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic determinants of carbapenem therapy in neonates and children.
    Blumer JL
    Pediatr Infect Dis J; 1996 Aug; 15(8):733-7. PubMed ID: 8858691
    [No Abstract]   [Full Text] [Related]  

  • 6. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN; Mendes C; Turner PJ; Masterton R
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the susceptibility trends to meropenem in a nationwide collection of clinical isolates in Japan: a longitudinal analysis from 2002 to 2006.
    Ishii Y; Yamaguchi K;
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):346-50. PubMed ID: 18339507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meropenem (meronem) in the complex treatment of severe infectious inflammatory diseases in neonates].
    Dement'eva GM; Kushnareva MV; Frolova MI; Chernonog IN; Markhuliia KhM; Balashova ED; Saak'iants EA; Samoĭlova LN
    Antibiot Khimioter; 2001; 46(12):17-21. PubMed ID: 12108088
    [No Abstract]   [Full Text] [Related]  

  • 10. Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit.
    Toltzis P; Dul M; O'Riordan MA; Melnick D; Lo M; Blumer J
    Pediatr Crit Care Med; 2009 Jan; 10(1):49-54. PubMed ID: 19057450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.
    Jones RN
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):169, 197-8. PubMed ID: 11777654
    [No Abstract]   [Full Text] [Related]  

  • 12. Rational choice of an oral beta-lactam antibiotic.
    Periti P
    J Chemother; 1997 Sep; 9 Suppl 4():1-23. PubMed ID: 9373786
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
    Turner PJ
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():9-23. PubMed ID: 11065145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of monovalent cations in tetracycline antibiotic transport in bacteria].
    Klypina NS; Myl'nikova SI; Bondareva LV; Plakunov VK
    Izv Akad Nauk SSSR Biol; 1987; (1):146-50. PubMed ID: 3819165
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of Meropenem for Use in Bacterial Keratitis.
    Sueke H; Kaye S; Wilkinson MC; Kennedy S; Kearns V; Zheng Y; Roberts P; Tuft S; Neal T
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5731-8. PubMed ID: 26325409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal community-acquired pneumonia: pathogens and treatment.
    Wang H; Tang J; Xiong Y; Li X; Gonzalez F; Mu D
    J Paediatr Child Health; 2010 Nov; 46(11):668-72. PubMed ID: 20796185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.